Primary Prevention of Cardiovascular Disease With HRT

Kate Maclaran; John C Stevenson


Women's Health. 2012;8(1):63-74. 

In This Article

Future Perspective

Over the next 5–10 years the public health implications of reducing cardiovascular risk in postmenopausal women will become increasingly important as rates of CHD continue to rise. We are unlikely to see large-scale randomized trials such as WHI in the near future, but smaller studies with surrogate markers will help further investigate the timing hypothesis and identify those who may receive greatest benefit from HRT. Ongoing research will also hopefully clarify the risks and benefits of low-dose and transdermal estrogens in older women or those with pre-existing CHD, and help gain greater insight regarding the optimum duration of estrogen therapy to impact on cardiovascular risk.

Further information is needed about the varying metabolic effects of different estrogens and progestogens, and whether this translates to clinical outcomes. In the future we will hopefully see the development of novel SERMs that have cardiovascular benefit but avoid adverse effects on breast tissue or the endometrium.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.